Clinical Implications of Clopidogrel Pharmacogenomics – Pre-lecture video – Video


Clinical Implications of Clopidogrel Pharmacogenomics - Pre-lecture video
Following this pre-lecture video, you should be able to understand how genetic and environmental factors play a role in clopidogrel efficacy, who should receive 2C19 genetic testing, and what therapeutic options are available in patients with a *2 CYP 2C19 allele.

By: Sean Kane

Read more:
Clinical Implications of Clopidogrel Pharmacogenomics - Pre-lecture video - Video

Pharmacogenomics: Regulatory aspects in Greece and the EU. – Video


Pharmacogenomics: Regulatory aspects in Greece and the EU.
Pharmacogenomics: Regulatory aspects in Greece and the EU. In: 7th Golden Helix Pharmacogenomics Day, University of Patras, Conference and Convention Centre, Saturday, 20 October 2012 B iota; omicron; epsilon; pi; iota; sigma; tau; #942; mu; epsilon; sigmaf;, mu; omicron; chi; lambda; #972; sigmaf; alpha; nu; #940; pi; tau; upsilon; xi; eta; sigmaf; tau; eta; sigmaf; Kappa; omicron; iota; nu; omega; nu; #943; alpha; sigmaf;, Sigma; upsilon; nu; epsilon; delta; rho; iota; alpha; kappa; #972; kappa; alpha; iota; Pi; omicron; lambda; iota; tau; iota; sigma; tau; iota; kappa; #972; Kappa; #941; nu; tau; rho; omicron; tau; omicron; upsilon; Pi; alpha; nu; epsilon; pi; iota; sigma; tau; eta; mu; #943; omicron; upsilon; Pi; alpha; tau; rho; #974; nu;, Pi; #940; tau; rho; alpha;, 18 -- 20 Omicron; kappa; tau; omega; beta; rho; #943; omicron; upsilon; 2012

By: Chi; alpha; rho; #940; lambda; alpha; mu; pi; omicron; sigmaf; Kappa; alpha; tau; sigma; omicron; #973; lambda; alpha; sigmaf;

See the rest here:
Pharmacogenomics: Regulatory aspects in Greece and the EU. - Video

OMICS Group – Journal of Pharmacogenomics and Pharmacoproteomics-2153-0645-3-112 – Video


OMICS Group - Journal of Pharmacogenomics and Pharmacoproteomics-2153-0645-3-112
OMICS Group is an Open Access publication model that enables the dissemination of research articles to the global community. Thus, all articles published under Open Access can be accessed by anyone.

By: OMICSGroup I Articles

View post:
OMICS Group - Journal of Pharmacogenomics and Pharmacoproteomics-2153-0645-3-112 - Video

Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic… – Video


Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic...
... evaluation of medicinal products Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Marc Maliepaard, CHMP-Pharmacogenomics Working Party member Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:29:13More inScience Technology

View post:
Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic... - Video

Session 6: Genomics in Patients with Japanese ancestry – Video


Session 6: Genomics in Patients with Japanese ancestry
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Yoshiaki Uyama, PMDA, Regulatory Science, Japan Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:26:16More inScience Technology

Read more:
Session 6: Genomics in Patients with Japanese ancestry - Video

Session 6: Genomics in Patients with Hispanic ancestry – Video


Session 6: Genomics in Patients with Hispanic ancestry
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Adrian Llerena, CHMP-Pharmacogenomics Working Party member Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:26:36More inScience Technology

Follow this link:
Session 6: Genomics in Patients with Hispanic ancestry - Video

Session 4: Pharmacogenomics guided treatments in clinical care: experience from… – Video


Session 4: Pharmacogenomics guided treatments in clinical care: experience from...
...patients and health care professionals (HCPs) Speaker: David Haerry, EATG, Belgium Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:7 0ratingsTime:14:30More inScience Technology

View post:
Session 4: Pharmacogenomics guided treatments in clinical care: experience from... - Video

Session 4: Pharmacogenomics: a long(er) learning curve? Opening keynote lecture – Video


Session 4: Pharmacogenomics: a long(er) learning curve? Opening keynote lecture
Session 4: Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs) Speaker: Hans Georg-Eichler, Senior Medical Officer, EMA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:4 0ratingsTime:19:01More inScience Technology

Read more from the original source:
Session 4: Pharmacogenomics: a long(er) learning curve? Opening keynote lecture - Video

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor… – Video


Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor...
...as a Therapy for Cystic Fibrosis Session 1: Pharmacogenomics: regulatory and methodological implications in early clinical development Speaker: Federico Goodsaid, Vertex Pharmaceuticals, USA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:1 0ratingsTime:32:26More inScience Technology

See the original post:
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor... - Video

Session 6: Closing remarks – Video


Session 6: Closing remarks
Session 6: Pharmacogenomics in the global landscape: Pharmacogenetics and Ethnicity Speaker: Tomas Salmonson, Chairman of the Committee for Medicinal Products for Human Use, EMA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:04:42More inScience Technology

Here is the original post:
Session 6: Closing remarks - Video

Session 4: Clinical implementation: a 7 year experience – Video


Session 4: Clinical implementation: a 7 year experience
Session 4: Pharmacogenomics guided treatments in clinical care: experience from patients and health care professionals (HCPs) Speaker: Ronald van Schaik, Erasmus Medical Center, the Netherlands Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:28:40More inScience Technology

Originally posted here:
Session 4: Clinical implementation: a 7 year experience - Video

Session 3: Post-approval pharmacogenomics: impact on Risk Management Plans and Information – Video


Session 3: Post-approval pharmacogenomics: impact on Risk Management Plans and Information
Speaker: Isabelle Moulon, Head of Sector for Medical information, EMA Workshop on Pharmacogenomics: from science to clinical care (8 October 2012)From:emainfoViews:0 0ratingsTime:10:23More inScience Technology

See the original post here:
Session 3: Post-approval pharmacogenomics: impact on Risk Management Plans and Information - Video